An un­ortho­dox pro­pos­al for Bio­gen's Medicare-man­dat­ed Aduhelm tri­al

Bio­gen has gone full blitz since Medicare an­nounced it would on­ly cov­er its new Alzheimer’s drug when used in clin­i­cal tri­als, ac­cus­ing the agency of dis­crim­i­nat­ing against Alzheimer’s pa­tients and try­ing to get physi­cians to change reg­u­la­tors’ minds. Crit­ics, mean­while, cheered what they see as a nec­es­sary wall pro­tect­ing pay­ers and pa­tients from an un­proven and un­safe drug.

Far less at­ten­tion, though, has gone to what a Medicare-fund­ed clin­i­cal tri­al would ac­tu­al­ly look like. Bio­gen has op­er­at­ed as if it would be a stan­dard late-stage Alzheimer’s tri­al, en­rolling a cou­ple thou­sand pa­tients and giv­ing half place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER